Herpes simplex virus (HSV) infection of the neonate is uncommon, but genital herpes infections in adults are very common. Thus, although treating an infant with neonatal herpes is a relatively rare occurrence, managing infants potentially exposed to HSV at the time of delivery occurs more frequently. The risk of transmitting HSV to an infant during delivery is determined in part by the mother's previous immunity to HSV. Women with primary genital HSV infections who are shedding HSV at delivery are 10 to 30 times more likely to transmit the virus to their newborn infants than are women with recurrent HSV infection who are shedding virus at delivery. With the availability of commercial serological tests that reliably can distinguish type-specific HSV antibodies, it is now possible to determine the type of maternal infection and, thus, further refine management of infants delivered to women who have active genital HSV lesions. The management algorithm presented herein uses both serological and virological studies to determine the risk of HSV transmission to the neonate who is delivered to a mother with active herpetic genital lesions and tailors management accordingly. The algorithm does not address the approach to asymptomatic neonates delivered to women with a history of genital herpes but no active lesions at delivery. Pediatrics 2013;131:e635-e646
INTRODUCTION
Herpes simplex virus (HSV) infection of the neonate is an uncommon occurrence, with an estimated 1500 cases diagnosed annually in the United States from a birth cohort of more than 4 000 000. In contrast, genital herpes infections in adults are very common. Between 1 in 4 and 1 in 5 adults in the United States has genital herpes caused by HSV type 2 (HSV-2). 1, 2 In addition, HSV type 1 (HSV-1) now accounts for at least 20% and, in some locales, more than 50% of cases of genital herpes in the United States. 3, 4 Therefore, managing infants potentially exposed to HSV at the time of delivery is not uncommon, and prevention of the devastating outcomes of neonatal HSV disease is paramount.
Current recommendations for the management of infants after intrapartum exposure are based on expert opinion, because a randomized controlled trial to determine whether an exposed neonate should be treated would be unethical. However, the existing recommendations do not take into account recent information correlating risk of transmission with type of maternal infection (primary versus recurrent) at the time of delivery. 5 The algorithm contained within this American Academy of Pediatrics (AAP) clinical report for the diagnostic and therapeutic approach to the neonate with known potential exposure to HSV during the perinatal period incorporates the most current scientific understanding of the biology, epidemiology, and pathology of HSV infection and disease.
TERMINOLOGY OF HSV INFECTION AND DISEASE
When an individual with no HSV-1 or HSV-2 antibody acquires either virus in the genital tract, a first-episode primary infection results. If a person with preexisting HSV-1 antibody acquires HSV-2 genital infection (or vice versa), a firstepisode nonprimary infection ensues. Viral reactivation from latency and subsequent antegrade translocation of virus back to skin and mucosal surfaces produces a recurrent infection.
Genital HSV infection can be either clinically apparent (eg, genital lesions) or inapparent (asymptomatic, or subclinical). Transmission to the neonate at the time of birth can occur with either presentation.
The distinction between neonatal HSV infection and neonatal HSV disease warrants discussion. Infection occurs when viral replication has been established, but the virus is not causing illness. Disease occurs when viral replication produces clinical signs of illness (eg, skin lesions, encephalitis, hepatitis). Once an infant is infected with HSV, progression to neonatal HSV disease is virtually certain. In an effort to prevent this progression from neonatal infection to neonatal disease, experts have recommended for many years that parenteral acyclovir be administered preemptively to HSV-infected neonates. 6 
RISK OF MATERNAL INFECTION DURING PREGNANCY
Recurrent infections are the most common form of genital HSV during pregnancy. 7 Approximately 10% of HSV-2-seronegative pregnant women have an HSV-2-seropositive sexual partner and, thus, are at risk for contracting a primary HSV-2 infection during the pregnancy 8 and transmitting the virus to their infants during delivery. Approximately one-fifth to one-third of women of childbearing age are seronegative for both HSV-1 and HSV-2, 9,10 and, among discordant couples, the chance that a woman will acquire either virus during pregnancy is estimated to be 3.7%. 11 For women who are already seropositive for HSV-1, the estimated chance of HSV-2 acquisition during the pregnancy is 1.7%. 11 Approximately twothirds of women who acquire genital herpes during pregnancy remain asymptomatic and have no symptoms to suggest a genital HSV infection. 11 This is consistent with the finding that 60% to 80% of women who deliver an HSV-infected infant have a clinically unapparent genital HSV infection at the time of delivery and have neither a past history of genital herpes nor a sexual partner reporting a history of genital HSV. [12] [13] [14] 
RISK OF NEONATAL HSV INFECTION
HSV infection of the newborn infant is acquired during 1 of 3 distinct times: intrauterine (in utero), intrapartum (perinatal), and postpartum (postnatal). The time of transmission of HSV-1 or HSV-2 for the overwhelming majority of infected infants (∼85%) is in the intrapartum period. An additional 10% of infected neonates acquire HSV-1 postnatally from either a maternal or nonmaternal source, and the final 5% are infected with HSV-2 or HSV-1 in utero. Five factors known to influence transmission of HSV from mother to neonate are: (Fig 1) . 5, [15] [16] [17] [18] The largest assessment of the influence of type of maternal infection on likelihood of neonatal transmission is a landmark study involving almost 60 000 women in labor who did not have clinical evidence of genital HSV disease, approximately 40 000 of whom had cultures performed within 48 hours of delivery (Fig 1) . 5 Of these, 121 women were identified who were asymptomatically shedding HSV and who had sera available for analysis. In this large trial, 57% of infants delivered to women with first-episode primary HSV infection developed neonatal HSV disease, compared with 25% of infants delivered to women with first-episode nonprimary infection and 2% of infants delivered to women with recurrent HSV disease (Fig 1) . 5 
CLINICAL MANIFESTATIONS OF NEONATAL HSV DISEASE
HSV infections acquired either intrapartum or postpartum can be classified as: (1) 31 and their use is not recommended.
DIAGNOSIS OF NEONATAL HSV DISEASE
Isolation of HSV by culture remains the definitive diagnostic method of establishing neonatal HSV disease. If skin lesions are present, a scraping of the vesicles should be transferred in appropriate viral transport media on ice to a diagnostic virology laboratory. 6 Other sites from which specimens should be obtained for culture of HSV include the conjunctivae, mouth, nasopharynx, and rectum ("surface cultures"). 6 Specimens for viral culture from mucosal body sites may be combined before inoculating in cell culture to decrease costs, because the important information gathered from such cultures is the presence or absence of replicating virus rather than its precise body site. The sensitivity of PCR assay on surface specimens has not been studied; if used, surface PCR assay should be performed in addition to (and not instead of) the gold-standard surface culture. Rapid diagnostic techniques also are available, such as direct fluorescent antibody staining of vesicle scrapings or enzyme immunoassay detection of HSV antigens. These techniques are as specific but slightly less sensitive than culture.
The diagnosis of neonatal HSV CNS disease has been greatly enhanced by PCR testing of cerebrospinal fluid (CSF) specimens, [32] [33] [34] [35] [36] [37] [38] and PCR assay is now the method of choice for documenting CNS involvement in an infant
FIGURE 1
Type of maternal infection and risk of HSV transmission to the neonate. 5 suspected of having HSV disease. However, PCR assay of CSF should only be performed in conjunction with HSV surface cultures, given that up to 40% of infants with disseminated disease will not have CNS involvement, and, by definition, no infants with SEM disease will have CNS involvement. The sensitivity of CSF PCR testing in neonatal HSV disease ranges from 75% to 100%. 33, 36, 38 PCR analysis of CSF also should play a role in determining the duration of antiviral therapy, because available data suggest that having HSV DNA detected in CSF at or after completion of intravenous therapy is associated with poor outcomes. 36, 37 All infants with a positive CSF PCR assay result for HSV DNA at the beginning of antiviral therapy should have a repeat lumbar puncture near the end of treatment to determine that HSV DNA has been cleared from the CNS. 24 Infants whose PCR assay result remains positive should continue to receive intravenous antiviral therapy until the CSF PCR assay result is negative. 24, 36 Application of PCR testing to blood specimens from infants with suspected HSV disease appears promising, [37] [38] [39] [40] [41] [42] and, in the 2012 Red Book, 6 PCR assay of blood has been added to the laboratory evaluation for neonatal HSV disease. Data are insufficient at the current time to allow the use of serial PCR assays of blood to establish response to antiviral therapy or to guide decisions about the duration of therapy.
Serological testing is not helpful in the diagnosis of neonatal HSV infection, because transplacentally acquired maternal HSV IgG is present in most infants, given the substantial proportions of the adult American population who are HSV-1 and/or HSV-2 seropositive.
PREVENTION OF NEONATAL HSV DISEASE
Cesarean delivery in a woman with active genital lesions can reduce the infant' s risk of acquiring HSV. 5, 18 In 
ALGORITHM FOR MANAGEMENT OF ASYMPTOMATIC NEONATES BORN VAGINALLY OR BY CESAREAN DELIVERY TO WOMEN WITH ACTIVE GENITAL HSV LESIONS (FIGS 2 AND 3)
The risk of transmitting HSV to the newborn infant during delivery is influenced directly by the mother' s previous immunity to HSV; women who have primary genital HSV infections who are shedding HSV at delivery are 10 to 30 times more likely to transmit the virus to their newborn infants than women with a recurrent infection. 5 The increased risk is attributable both to lower concentrations of transplacental HSV-specific antibodies (which also are less reactive to expressed polypeptides) in women with primary infection 19 and to the higher quantities of HSV that are shed for a longer period of time in the maternal genital tract in comparison with women who have recurrent genital HSV infection. 54 However, a substantial percentage of women with first clinical episodes of symptomatic genital herpes actually are experiencing reactivation of a previously unrecognized genital herpetic infection. 55 Thus, to tailor management of exposed neonates according to their degree of risk, one must distinguish primary versus recurrent maternal HSV infection in a manner that relies on more than just the history, or lack thereof, of genital herpes in the woman or her partner (s). Ideally, detection of HSV DNA from genital swabs obtained from women in labor would identify both symptomatic and asymptomatic HSV shedding, allowing for focused management of only those infants who are exposed; however, the technology to accomplish this on a broad scale is not readily available commercially at this time.
With the approval of commercially available serological tests that can reliably distinguish type-specific HSV antibodies ( Table 2) .
Management of Asymptomatic Neonates After Vaginal or Cesarean Delivery to Women With Lesions at Delivery and History of Genital HSV Preceding Pregnancy
For women with a history of genital herpes preceding the pregnancy, the likelihood that the current outbreak represents reactivation of latent HSV is high, and, therefore, the likelihood of transmission to the infant is low (2%). Skin and mucosal specimens (conjunctivae, mouth, nasopharynx, and rectum, and scalp electrode site, if present) should be obtained from the neonate for culture (and PCR assay, if desired) at approximately 24 hours after delivery (BII), and blood should be sent for HSV DNA PCR assay. Acyclovir need not be started as long as the infant remains asymptomatic (BIII).
The importance of waiting until approximately 24 hours after delivery to obtain virological studies is based on the fact that a positive virological test result at that point represents actively replicating virus on the infant' s mucosa, whereas a positive test result shortly after birth could reflect only transient maternal contamination that may not lead to replication with resulting neonatal HSV disease. 56 It is permissible to discharge an asymptomatic infant after
FIGURE 2
Algorithm for the evaluation of asymptomatic neonates after vaginal or cesarean delivery to women with active genital herpes lesions. ALT, alanine aminotransferase; D/C, discontinue.
e640 FROM THE AMERICAN ACADEMY OF PEDIATRICS 48 hours of negative HSV cultures (and negative PCR assay results) if other discharge criteria have been met, there is ready access to medical care, and a person who is able to comply fully with instructions for home observation will be present (BIII). If any of these conditions is not met, the infant should be observed in the hospital until HSV cultures are finalized as negative or are negative for 96 hours after being set up in cell culture, whichever is shorter.
If the surface and blood virological study results are negative at 5 days, the infant should be evaluated if signs or symptoms of neonatal HSV disease develop during the first 6 weeks of life (AII). Conversely, if the surface and blood virological study results become positive, thus confirming neonatal HSV infection, the infant should undergo a complete evaluation (lumbar puncture with CSF sent for indices and HSV DNA PCR assay, in addition to serum alanine transaminase) to determine the extent of disease, and intravenous acyclovir should be initiated as soon as possible. If the evaluation findings are normal, indicating that the neonate has HSV infection but that it has not yet progressed to HSV disease, the infant should be treated empirically with intravenous acyclovir for 10 days to prevent progression from infection to disease (preemptive therapy) (BIII). If the evaluation findings are abnormal,
FIGURE 3
Algorithm for the treatment of asymptomatic neonates after vaginal or cesarean delivery to women with active genital herpes lesions. ALT, alanine aminotransferase; D/C, discontinue. For women without a history of genital herpes preceding pregnancy, the presence of genital lesions at delivery could represent first-episode primary infection (with a risk of transmission to the newborn infant of 57%), first-episode nonprimary infection (with a risk of transmission to the newborn infant of 25%), or recurrent infection (with a risk of transmission to the newborn infant of 2%). Thus, with the availability of type-specific serological testing, the practitioner can determine which type of infection the outbreak represents, given that the risks to the infant are so disparate. Accordingly, serological testing should be performed to determine the type of HSV infection in the mother to delineate between the 3 (Table 1) . 
